What The Viewpoint Says:
This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.
Authors:
Muhammad Bilal Abid, M.D., M.R.C.P., of the Medical College of Wisconsin in Milwaukee, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
https:/
/
media.
jamanetwork.
com/
(doi:10.1001/jamaoncol.2020.2367)
Editor’s Note:
Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
###
Media advisory:
The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https:/
/
jamanetwork.
com/
journals/
jamaoncology/
fullarticle/
10.
1001/
jamaoncol.
2020.
2367?guestAccessKey=
94f1c911-3f85-480f-869f-39448d5a8056&utm_source=
For_The_Media&utm_medium=
referral&utm_campaign=
ftm_links&utm_content=
tfl&utm_term=
052020
This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-05/jn-cai051920.php
